Share
.webp)
.webp)
.webp)
.webp)
Andreas Amrein
Stallergenes Greer, a global leader in allergy therapeutics, has appointed Andreas Amrein as Chief Executive Officer.
He will succeed Michele Antonelli, who will retire at the end of March after over a decade of service with the company.
Mr. Amrein brings more than 25 years of pharmaceutical industry experience, having held leadership roles at major companies including Novartis, Abbott, and Shire Takeda. His expertise spans commercial leadership, strategic planning, finance, and business development across a broad range of therapeutic areas and international markets. Most recently, he served as Managing Director and member of the Global Leadership Team at Advanced Clinical, a global contract research organization, since 2021.
The company extends its gratitude to Mr. Antonelli for his significant contributions and leadership over the past ten years and looks forward to continued growth under Mr. Amrein’s direction.
